FDA cancels meeting to review Lilly’s Cymbalta

The Food and Drug Administration has canceled a meeting to review Eli Lilly and Co. antidepressant Cymbalta for a new use
against chronic pain.

The agency said in a statement Tuesday that the Jan. 28 meeting was canceled "to allow
time for the FDA to review new information," about the proposed use.

Lilly shares fell 82 cents, or 2.3 percent,
to $35 in early-afternoon trading.

Calls placed to Indianapolis-based Lilly on Tuesday were not immediately returned.

Lilly withdrew an application in November 2008 after FDA reviewers questioned the methodology and dosing in some of
the company’s trials.

The company submitted a new application last summer that included a study of Cymbalta for
chronic pain caused by osteoarthritis, along with new data from a study of lower back pain.

Cymbalta is already
approved to treat depression, generalized anxiety disorder, diabetic nerve pain and the pain ailment fibromyalgia.

The drug is Lilly’s second-best selling product, behind the anti-psychotic Zyprexa. Cymbalta generated $2.24 billion in
sales through the first three quarters of 2009.

Lilly faces the loss of patents protecting several of its top-selling
drugs in the next few years. The patent protecting Zyprexa, which generated more than $4 billion in 2008, expires in 2011.
Cymbalta’s patent expires in 2013.

Please enable JavaScript to view this content.

Story Continues Below

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our updated comment policy that will govern how comments are moderated.

{{ articles_remaining }}
Free {{ article_text }} Remaining
{{ articles_remaining }}
Free {{ article_text }} Remaining Article limit resets on
{{ count_down }}